Safety and effectiveness of very-high-power, short-duration ablation in patients with atrial fibrillation: Preliminary results

Abstract Funding Acknowledgements Type of funding sources: None. Background Pulmonary vein isolation (PVI) is at the forefront of rhythm control strategies in patients with atrial fibrillation (AF). A very-high-power, short-duration (vHPSD) catheter was designed to improve the effectiveness of AF ab...

Full description

Saved in:
Bibliographic Details
Published in:Europace (London, England) England), 2023-05, Vol.25 (Supplement_1)
Main Authors: Lodzinski, P, Mitrzak, K, Peller, M, Krzowski, B, Maciejewski, C, Balsam, P, Marchel, M, Grabowski, M
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue Supplement_1
container_start_page
container_title Europace (London, England)
container_volume 25
creator Lodzinski, P
Mitrzak, K
Peller, M
Krzowski, B
Maciejewski, C
Balsam, P
Marchel, M
Grabowski, M
description Abstract Funding Acknowledgements Type of funding sources: None. Background Pulmonary vein isolation (PVI) is at the forefront of rhythm control strategies in patients with atrial fibrillation (AF). A very-high-power, short-duration (vHPSD) catheter was designed to improve the effectiveness of AF ablation within a shorter procedure time. We aimed to compare the effectiveness and safety of PVI ablation between this vHPSD ablation mode (90W/4s) and conventional index-guided ablation (up to 40W/indexed). Methods This single-center, retrospective, observational study enrolled 148 patients with AF, referred for catheter ablation between December 16, 2019 and July 29, 2022. In 77 procedures (mean age: 59.7±12.0 years; 61.0% male; 74.0% paroxysmal), a vHPSD catheter was used (vHPSD-group), and 71 patients (mean age: 58.1±11.6 years; 70.4% male; 67.6% paroxysmal) were treated with a ablation index catheter (AI-group). The study assessed the recurrence of AF at 3- and 6-months after ablation. The outcomes also included the amount of opioids administered during the procedure and the incidence of treatment-emergent adverse events. Additionally, procedural factors, such as total procedure time, fluoroscopy time and radiofrequency application time were compared between the groups. Results At 3 months, AF was found to recur in 14.29% (11/77) of patients in the vHPSD-group and in 30.99% (22/71) of patients in the AI-group (p=0.02). At 6 months, 18.31% (13/71) patients reported AF recurrence in the vHPSD-group and 32.73 % (18/55) in the AI-group (p=0.09). There was no difference in treatment-emergent adverse events between the two groups (3.9% vs. 2.8%; p=1.00). One severe adverse event (a cerebral vascular accident) was observed in the vHPSD-group. The mean dose of remifentanil was reported to be lower during vHPSD-based PVI (p
doi_str_mv 10.1093/europace/euad122.745
format article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10207292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/europace/euad122.745</oup_id><sourcerecordid>10.1093/europace/euad122.745</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1875-b0e4c73f6abd031a3733f741fcf92da3f565b9532cf42ff9b8e62c06679b82d3</originalsourceid><addsrcrecordid>eNqNkdtKAzEQhoMoWKtv4EUewLU57KHxRqR4goKCvQ_Z7KQb2W6WZLelNz67KVsF77yaD2b-n5n5Ebqm5JYSwWcweNcpDRFURRm7LdLsBE1oxlnCiGCnkYkQSUaZOEcXIXwSQgomsgn6-lAG-j1WbYXBGNC93UILIWBn8Bb8Pqntuk46twN_g0PtfJ9Ug1e9dS1WZTOCbXEXCdo-4J3ta6x6b1WDjS29bcahO_zuobEb2yq_xx7C0PThEp0Z1QS4OtYpWj09rhYvyfLt-XXxsEw0nRdZUhJIdcFNrsqKcKp4wbkpUmq0EaxS3GR5Vop4rjYpM0aUc8iZJnleRGQVn6L70bYbyg1UOi7qVSM7bzdxGemUlX87ra3l2m0lJezwKBYd0tFBexeCB_MrpkQeQpA_IchjCDKGEGWzUeaG7n-Kb56lk_8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and effectiveness of very-high-power, short-duration ablation in patients with atrial fibrillation: Preliminary results</title><source>Open Access: Oxford University Press Open Journals</source><source>Oxford Journals Online</source><source>PubMed Central</source><creator>Lodzinski, P ; Mitrzak, K ; Peller, M ; Krzowski, B ; Maciejewski, C ; Balsam, P ; Marchel, M ; Grabowski, M</creator><creatorcontrib>Lodzinski, P ; Mitrzak, K ; Peller, M ; Krzowski, B ; Maciejewski, C ; Balsam, P ; Marchel, M ; Grabowski, M</creatorcontrib><description>Abstract Funding Acknowledgements Type of funding sources: None. Background Pulmonary vein isolation (PVI) is at the forefront of rhythm control strategies in patients with atrial fibrillation (AF). A very-high-power, short-duration (vHPSD) catheter was designed to improve the effectiveness of AF ablation within a shorter procedure time. We aimed to compare the effectiveness and safety of PVI ablation between this vHPSD ablation mode (90W/4s) and conventional index-guided ablation (up to 40W/indexed). Methods This single-center, retrospective, observational study enrolled 148 patients with AF, referred for catheter ablation between December 16, 2019 and July 29, 2022. In 77 procedures (mean age: 59.7±12.0 years; 61.0% male; 74.0% paroxysmal), a vHPSD catheter was used (vHPSD-group), and 71 patients (mean age: 58.1±11.6 years; 70.4% male; 67.6% paroxysmal) were treated with a ablation index catheter (AI-group). The study assessed the recurrence of AF at 3- and 6-months after ablation. The outcomes also included the amount of opioids administered during the procedure and the incidence of treatment-emergent adverse events. Additionally, procedural factors, such as total procedure time, fluoroscopy time and radiofrequency application time were compared between the groups. Results At 3 months, AF was found to recur in 14.29% (11/77) of patients in the vHPSD-group and in 30.99% (22/71) of patients in the AI-group (p=0.02). At 6 months, 18.31% (13/71) patients reported AF recurrence in the vHPSD-group and 32.73 % (18/55) in the AI-group (p=0.09). There was no difference in treatment-emergent adverse events between the two groups (3.9% vs. 2.8%; p=1.00). One severe adverse event (a cerebral vascular accident) was observed in the vHPSD-group. The mean dose of remifentanil was reported to be lower during vHPSD-based PVI (p&lt;0.0001). The vHPSD-based PVI was associated with shorter radiofrequency application time (p&lt;0.0001), fluoroscopy time (p&lt;0.0001), and total procedure time (p&lt;0.0001). Conclusions This study suggests that the vHPSD-quided PVI is equally effective and safe with reference to short-term clinical observation as conventional ablation. Also, the vHPSD ablation may allow to reduce the dosage of analgesics during significantly shorter procedures.</description><identifier>ISSN: 1099-5129</identifier><identifier>EISSN: 1532-2092</identifier><identifier>DOI: 10.1093/europace/euad122.745</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Europace (London, England), 2023-05, Vol.25 (Supplement_1)</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207292/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207292/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids></links><search><creatorcontrib>Lodzinski, P</creatorcontrib><creatorcontrib>Mitrzak, K</creatorcontrib><creatorcontrib>Peller, M</creatorcontrib><creatorcontrib>Krzowski, B</creatorcontrib><creatorcontrib>Maciejewski, C</creatorcontrib><creatorcontrib>Balsam, P</creatorcontrib><creatorcontrib>Marchel, M</creatorcontrib><creatorcontrib>Grabowski, M</creatorcontrib><title>Safety and effectiveness of very-high-power, short-duration ablation in patients with atrial fibrillation: Preliminary results</title><title>Europace (London, England)</title><description>Abstract Funding Acknowledgements Type of funding sources: None. Background Pulmonary vein isolation (PVI) is at the forefront of rhythm control strategies in patients with atrial fibrillation (AF). A very-high-power, short-duration (vHPSD) catheter was designed to improve the effectiveness of AF ablation within a shorter procedure time. We aimed to compare the effectiveness and safety of PVI ablation between this vHPSD ablation mode (90W/4s) and conventional index-guided ablation (up to 40W/indexed). Methods This single-center, retrospective, observational study enrolled 148 patients with AF, referred for catheter ablation between December 16, 2019 and July 29, 2022. In 77 procedures (mean age: 59.7±12.0 years; 61.0% male; 74.0% paroxysmal), a vHPSD catheter was used (vHPSD-group), and 71 patients (mean age: 58.1±11.6 years; 70.4% male; 67.6% paroxysmal) were treated with a ablation index catheter (AI-group). The study assessed the recurrence of AF at 3- and 6-months after ablation. The outcomes also included the amount of opioids administered during the procedure and the incidence of treatment-emergent adverse events. Additionally, procedural factors, such as total procedure time, fluoroscopy time and radiofrequency application time were compared between the groups. Results At 3 months, AF was found to recur in 14.29% (11/77) of patients in the vHPSD-group and in 30.99% (22/71) of patients in the AI-group (p=0.02). At 6 months, 18.31% (13/71) patients reported AF recurrence in the vHPSD-group and 32.73 % (18/55) in the AI-group (p=0.09). There was no difference in treatment-emergent adverse events between the two groups (3.9% vs. 2.8%; p=1.00). One severe adverse event (a cerebral vascular accident) was observed in the vHPSD-group. The mean dose of remifentanil was reported to be lower during vHPSD-based PVI (p&lt;0.0001). The vHPSD-based PVI was associated with shorter radiofrequency application time (p&lt;0.0001), fluoroscopy time (p&lt;0.0001), and total procedure time (p&lt;0.0001). Conclusions This study suggests that the vHPSD-quided PVI is equally effective and safe with reference to short-term clinical observation as conventional ablation. Also, the vHPSD ablation may allow to reduce the dosage of analgesics during significantly shorter procedures.</description><issn>1099-5129</issn><issn>1532-2092</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqNkdtKAzEQhoMoWKtv4EUewLU57KHxRqR4goKCvQ_Z7KQb2W6WZLelNz67KVsF77yaD2b-n5n5Ebqm5JYSwWcweNcpDRFURRm7LdLsBE1oxlnCiGCnkYkQSUaZOEcXIXwSQgomsgn6-lAG-j1WbYXBGNC93UILIWBn8Bb8Pqntuk46twN_g0PtfJ9Ug1e9dS1WZTOCbXEXCdo-4J3ta6x6b1WDjS29bcahO_zuobEb2yq_xx7C0PThEp0Z1QS4OtYpWj09rhYvyfLt-XXxsEw0nRdZUhJIdcFNrsqKcKp4wbkpUmq0EaxS3GR5Vop4rjYpM0aUc8iZJnleRGQVn6L70bYbyg1UOi7qVSM7bzdxGemUlX87ra3l2m0lJezwKBYd0tFBexeCB_MrpkQeQpA_IchjCDKGEGWzUeaG7n-Kb56lk_8</recordid><startdate>20230524</startdate><enddate>20230524</enddate><creator>Lodzinski, P</creator><creator>Mitrzak, K</creator><creator>Peller, M</creator><creator>Krzowski, B</creator><creator>Maciejewski, C</creator><creator>Balsam, P</creator><creator>Marchel, M</creator><creator>Grabowski, M</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20230524</creationdate><title>Safety and effectiveness of very-high-power, short-duration ablation in patients with atrial fibrillation: Preliminary results</title><author>Lodzinski, P ; Mitrzak, K ; Peller, M ; Krzowski, B ; Maciejewski, C ; Balsam, P ; Marchel, M ; Grabowski, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1875-b0e4c73f6abd031a3733f741fcf92da3f565b9532cf42ff9b8e62c06679b82d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lodzinski, P</creatorcontrib><creatorcontrib>Mitrzak, K</creatorcontrib><creatorcontrib>Peller, M</creatorcontrib><creatorcontrib>Krzowski, B</creatorcontrib><creatorcontrib>Maciejewski, C</creatorcontrib><creatorcontrib>Balsam, P</creatorcontrib><creatorcontrib>Marchel, M</creatorcontrib><creatorcontrib>Grabowski, M</creatorcontrib><collection>Open Access: Oxford University Press Open Journals</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Europace (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lodzinski, P</au><au>Mitrzak, K</au><au>Peller, M</au><au>Krzowski, B</au><au>Maciejewski, C</au><au>Balsam, P</au><au>Marchel, M</au><au>Grabowski, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and effectiveness of very-high-power, short-duration ablation in patients with atrial fibrillation: Preliminary results</atitle><jtitle>Europace (London, England)</jtitle><date>2023-05-24</date><risdate>2023</risdate><volume>25</volume><issue>Supplement_1</issue><issn>1099-5129</issn><eissn>1532-2092</eissn><abstract>Abstract Funding Acknowledgements Type of funding sources: None. Background Pulmonary vein isolation (PVI) is at the forefront of rhythm control strategies in patients with atrial fibrillation (AF). A very-high-power, short-duration (vHPSD) catheter was designed to improve the effectiveness of AF ablation within a shorter procedure time. We aimed to compare the effectiveness and safety of PVI ablation between this vHPSD ablation mode (90W/4s) and conventional index-guided ablation (up to 40W/indexed). Methods This single-center, retrospective, observational study enrolled 148 patients with AF, referred for catheter ablation between December 16, 2019 and July 29, 2022. In 77 procedures (mean age: 59.7±12.0 years; 61.0% male; 74.0% paroxysmal), a vHPSD catheter was used (vHPSD-group), and 71 patients (mean age: 58.1±11.6 years; 70.4% male; 67.6% paroxysmal) were treated with a ablation index catheter (AI-group). The study assessed the recurrence of AF at 3- and 6-months after ablation. The outcomes also included the amount of opioids administered during the procedure and the incidence of treatment-emergent adverse events. Additionally, procedural factors, such as total procedure time, fluoroscopy time and radiofrequency application time were compared between the groups. Results At 3 months, AF was found to recur in 14.29% (11/77) of patients in the vHPSD-group and in 30.99% (22/71) of patients in the AI-group (p=0.02). At 6 months, 18.31% (13/71) patients reported AF recurrence in the vHPSD-group and 32.73 % (18/55) in the AI-group (p=0.09). There was no difference in treatment-emergent adverse events between the two groups (3.9% vs. 2.8%; p=1.00). One severe adverse event (a cerebral vascular accident) was observed in the vHPSD-group. The mean dose of remifentanil was reported to be lower during vHPSD-based PVI (p&lt;0.0001). The vHPSD-based PVI was associated with shorter radiofrequency application time (p&lt;0.0001), fluoroscopy time (p&lt;0.0001), and total procedure time (p&lt;0.0001). Conclusions This study suggests that the vHPSD-quided PVI is equally effective and safe with reference to short-term clinical observation as conventional ablation. Also, the vHPSD ablation may allow to reduce the dosage of analgesics during significantly shorter procedures.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/europace/euad122.745</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1099-5129
ispartof Europace (London, England), 2023-05, Vol.25 (Supplement_1)
issn 1099-5129
1532-2092
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10207292
source Open Access: Oxford University Press Open Journals; Oxford Journals Online; PubMed Central
title Safety and effectiveness of very-high-power, short-duration ablation in patients with atrial fibrillation: Preliminary results
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T19%3A19%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20effectiveness%20of%20very-high-power,%20short-duration%20ablation%20in%20patients%20with%20atrial%20fibrillation:%20Preliminary%20results&rft.jtitle=Europace%20(London,%20England)&rft.au=Lodzinski,%20P&rft.date=2023-05-24&rft.volume=25&rft.issue=Supplement_1&rft.issn=1099-5129&rft.eissn=1532-2092&rft_id=info:doi/10.1093/europace/euad122.745&rft_dat=%3Coup_pubme%3E10.1093/europace/euad122.745%3C/oup_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1875-b0e4c73f6abd031a3733f741fcf92da3f565b9532cf42ff9b8e62c06679b82d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/europace/euad122.745&rfr_iscdi=true